Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

The economic impact of sight loss and blindness in the UK adult population

Authors: Lynne Pezzullo, Jared Streatfeild, Philippa Simkiss, Darren Shickle

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

To quantify the economic impact of sight loss and blindness in the United Kingdom (UK) population, including direct and indirect costs, and its burden on health.

Methods

Prevalence data on sight loss and blindness by condition, Census demographic data, data on indirect costs, and healthcare cost databases were used. Blindness was defined as best corrected visual acuity (BCVA) of < 6/60, and sight loss as BCVA < 6/12 to 6/60, in the better-seeing eye.

Results

Sight loss and blindness from age-related macular degeneration (AMD), cataract, diabetic retinopathy, glaucoma and under-corrected refractive error are estimated to affect 1.93 (1.58 to 2.31) million people in the UK. Direct health care system costs were £3.0 billion, with inpatient and day care costs comprising £735 million (24.6%) and outpatient costs comprising £771 million (25.8%). Indirect costs amounted to £5.65 (5.12 to 6.22) billion. The value of the loss of healthy life associated with sight loss and blindness was estimated to be £19.5 (15.9 to 23.3) billion or £7.2 (5.9 to 8.6) billion, depending on the set of disability weights used. For comparison with other published results using 2004 disability weights and the 2008 estimates, the total economic cost of sight loss and blindness was estimated to be £28.1 (24.0 to 32.5) billion in 2013. Using 2010 disability weights, the estimated economic cost of sight loss and blindness was estimated to be £15.8 (13.5 to 18.3) billion in 2013.

Conclusions

The large prevalence of sight loss and blindness in the UK population imposes significant costs on public funds, private expenditure, and health. Prevalence estimates relied on dated epidemiological studies and may not capture recent advances in treatment, highlighting the need for population-based studies that track the prevalence of sight-impairing eye conditions and treatment effects over time.
Appendix
Available only for authorised users
Literature
1.
2.
3.
World Health Organization. Universal eye health: a global action plan 2014-2019. Geneva, WHO Library; 2013.
4.
Access Economics. Future sight loss UK (1): The economic impact of partial sight and blindness in the UK adult population. Report for Royal National Institute of Blind People (RNIB). Access Economics. Canberra. 2009.
5.
6.
Köberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open. 2013;3(11):e003471.CrossRefPubMedPubMedCentral
7.
Cruess AF, Gordon KD, Bellan L, Mitchell S, Pezzullo ML. The cost of vision loss in Canada. 2. Results. Can J Ophthalmol. 2011;46(4):315–8.CrossRefPubMed
8.
Roberts CB, Hiratsuka Y, Yamada M, Pezzullo L, Yates K, Takano S, et al. Economic cost of visual impairment in Japan. Arch Ophthalmol. 2010;128(6):766–71.CrossRefPubMed
9.
Larg A, Moss JR, Cost-of-Illness Studies. A guide to critical evaluation. PharmacoEconomics. 2011;29(8):653–71.CrossRefPubMed
10.
Evans JR, Fletcher AE, Wormald RPL, Siu-Woon Ng E, Sterling S, Smeeth L, et al. Prevalence of visual impairment in people aged 75 years and older in Britain: results from the MRC trial of assessment and management of older people in the community. Br J Ophthalmol. 2002;86:795–800.CrossRefPubMedPubMedCentral
11.
Evans JR, Fletcher AE, Wormald RPL. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC trial of assessment and Management of Older People in the community. Br J Ophthalmol. 2004;88:365–70.CrossRefPubMedPubMedCentral
12.
Reidy A, Minassian DC, Vafidis G, Joseph J, Farrow S, Wu J, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. Br Med J. 1998;316:1643–6.CrossRef
13.
Evans JR, Fletcher AE, Wormald RPL. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain. Ophthalmology. 2004;111:513–7.CrossRefPubMed
14.
15.
Congdon N, O'Colmain B, Klaver CCW, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.CrossRefPubMed
16.
Congdon N, Vingerling JR, Klein BEK, West S, Friedman DS, Kempen J, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122:487–94.CrossRefPubMed
17.
Friedman DS, O'Colmain BJ, Munoz B, Tomany MA, McCarty C, de Jong PTVM, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.CrossRefPubMed
18.
Friedman DS, Wolfs RCW, O'Colmain BJ, Klein BE, Taylor HR, West S, et al. Prevalence of open angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532–8.CrossRefPubMed
19.
Kempen JH, O'Colmain BJ, Leske C, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–63.CrossRefPubMed
20.
Kempen JH, Mitchell P, Lee KE, Tielsch JM, Broman AT, Taylor HR, et al. The prevalence of refractive errors among adults in the United States, Western Europe and Australia. Arch Ophthalmol. 2004;122:495–505.CrossRefPubMed
21.
Das BN, Thompson JR, Patel R, Rosenthal AR. The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent. J R Soc Med. 1994;87:219–22.PubMedPubMedCentral
22.
Wormald RPL, Basauri E, Wright LA, Evans JR. The African Caribbean eye survey: risk factors for glaucoma in a sample of African Caribbean people living in London. Eye. 1994;8(3):315–20.CrossRefPubMed
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
Health and Social Care Board. Health and Social Care Expenditure Plans for Northern Ireland, 2012/13 – Supplementary analysis to the HSCB/PHA Commissioning Plan 2012/13. Northern Ireland; 2013.
41.
42.
43.
44.
45.
46.
47.
Williams B, Whatmough P, McGill J, Rushton L. Private funding of elective hospital treatment in England and Wales, 1997-98: national survey. Br Med J. 2000;320:904–5.CrossRef
48.
49.
Scuffham PA, Legood R, Wilson ECF, Kennedy-Martin T. The incidence and cost of injurious falls associated with visual impairment in the UK. Vis Impair Res. 2002;4(1):1–14.CrossRef
50.
51.
52.
53.
Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. PharmacoEconomics. 2004;22(3):165–84.CrossRefPubMed
54.
55.
56.
57.
58.
McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. Br J Ophthalmol 2001;85(3):322–326.
59.
60.
Organisation for Economic Cooperation and Development. OECD health data 2012. Paris 2012.
61.
62.
Access Economics. The cost of partial sight and blindness in the US. Canberra: Report for USC Vision. Access Economics; 2006.
63.
Access Economics. The cost of partial sight and blindness in Canada. Report for Canadian National Institute for the Blind (CNIB) and Canadian Ophthalmology Society. Access Economics, Canberra. 2008.
64.
Access Economics. The cost of partial sight and blindness in Japan. Report for Japan Ophthalmologists Association, National Institute of Sensory Organs, and Juntendo University WHO Collaborating Centre for the Prevention of Blindness. Access Economics. Canberra. 2008.
65.
66.
Lafuma A, Brezin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, et al. Evaluation of non-medical costs associated with visual impairment in four European countries – France, Italy, Germany, and the UK. PharmacoEconomics. 2006;24(2):193–205.CrossRefPubMed
67.
68.
Kleven HJ, Kreiner CT. The marginal cost of public funds: hours of work versus labour force participation. J Public Econ. 2006;90:1955–73.CrossRef
69.
70.
71.
Murray C, Lopez A. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global burden of disease and injury series; 1. Harvard School of Public Health: Cambridge; 1996.
72.
World Health Organization. The global burden of disease: 2004 update. Geneva, World Health Organization; 2004.
73.
Salomon J, Vos T, Hogan D, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380:2129–43.CrossRefPubMed
74.
Nord E. Disability weights in the global burden of disease 2010: unclear meaning and overstatement of international agreement. Health policy 2013;111(1):99–104.
75.
Taylor HR, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, et al. Disability weights for vision disorders in global burden of disease study. Lancet. 2012;381(9860):23.CrossRefPubMed
76.
Chen A, Jacobsen KH, Deshmukh AA, Cantor SB. The evolution of the disability-adjusted life year (DALY). Socio Econ Plan Sci. 2015;49:10–5.CrossRef
77.
Mason H, Jones-Lee M, Donaldson C. Modelling The monetary value of a QALY: a new approach based on UK data. Health Econ. 2008;18(8):933–50.CrossRef
78.
79.
80.
Frick KD, Kymes SM, Lee PP, Matchar DB, Pezzullo ML, Rein DB, Taylor HR. The cost of visual impairment: purposes, perspectives, and guidance. Invest Ophthalmol Vis Sci. 2010;51(4):1801–5.CrossRefPubMed
81.
82.
Brouwer WBF, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ. 2000;19:439–59.CrossRefPubMed
83.
Heitmueller A. The chicken or the egg? Endogeneity in labour market participation of informal carers in England. J Health Econ. 2007;26:536–59.CrossRefPubMed
84.
Rees P, Wohland P, Norman P, Boden P. Ethnic population projections for the UK, 2001-2051. J Popul Res. 2012;29:45–89.CrossRef
85.
Coleman D. Projections of the Ethnic Minority Populations of the United Kingdom. Population and Development Review. 2006-2056. 2010;36(3):441–86..
86.
Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol. 2003;135(4):471–6.CrossRefPubMed
87.
Gordois A, Cutler H, Pezzullo L, Gordon K, Cruess A, Winyard S, et al. An estimation of the worldwide economic and health burden of visual impairment. Global Public Health. 2012;7(5):465–81.CrossRefPubMed
88.
Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402–8.CrossRefPubMed
89.
90.
4-consulting. The economic impact of free eye examinations in Scotland. Report for Association of Optometrists. Kirkcaldy, Scotland. 2012.
91.
Metadata
Title
The economic impact of sight loss and blindness in the UK adult population
Authors
Lynne Pezzullo
Jared Streatfeild
Philippa Simkiss
Darren Shickle
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-2836-0

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue

Research article

Exploring organisational mechanisms in PRO-based follow-up in routine outpatient care - an interpretive description of the clinician perspective

Research article

Children and young people’s participation in developing interventions in health and well-being: a scoping review

Research article

Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

Research article

The role of the assistant practitioner in the clinical setting: a focus group study

Research article

Comparing the application of two theoretical frameworks to describe determinants of adverse medical device event reporting: secondary analysis of qualitative interview data

Research article

Operational assessment of point-of-care diagnostics in rural primary healthcare clinics of KwaZulu-Natal, South Africa: a cross-sectional survey